Tokyo University of Science Signs Research Agreement with Cytimmune Sciences to Investigate IO+ nanomedicines in combination with checkpoint inhibitors.
August 1, 2020, Rockville, MD — CytImmune has signed an agreement with the Tokyo University of Science, Division of Molecular Regulation of Inflammation and Immune Diseases, to investigate and confirm synergies between Cytimmune’s nanomedicines and existing checkpoint inhibitors. Small animal studies will be conducted and data shared between Cytimmune’s Rockville, Maryland, laboratories and the research laboratories of Professor Kouji Matsushima. These studies will investigate the potential to use inflammatory cytokines to enhance the performance of a class of cancer therapeutics known as checkpoint inhibitors in the treatment of solid tumor cancers.
About Cytimmune
Cytimmune is a privately held biotechnology company with operations in Rockville, Maryland, and Boston, Massachusetts. The company is a pioneer in nano-engineering, having developed an in vitro, synthetic immune system used for the rapid creation of fully humanized antibodies, and a set of novel technologies designed to improve the targeting, safety, and efficacy of systemically delivered combination cancer therapies. The company’s pipeline of nanomedicines are part of their IO+ platform — a nanoparticle-based delivery system that targets and attacks solid tumor cancers. Cytimmune’s lead product, CYT-6091, which delivers high-dose Tumor Necrosis Factor Alpha, has successfully completed a phase 1 clinical trial at the U.S. National Cancer Institute.
About the Tokyo University of Science and Professor Kouji Matsushima, PhD
The Tokyo University of Science is a prestigious Japanese University with a long history. The University was founded under the name "Tokyo Butsurigaku Koshujo" (Tokyo Academy of Physics) in 1881. In 1949, the Tokyo College of Science was reorganized under the new university system and became the "Tokyo University of Science" (TUS). Along with the advance of science and technology, departments covering a wide range of fields were set up, and today, TUS is the only general university for science and technology in Japan. As of 2016, it was the only private university in Japan to have produced a Nobel Prize winner and the only private university in Asia to produce Nobel Prize winners within the natural sciences field.
Professor Kouji Matsushima, PhD, is a distinguished professor and researcher currently associated with the Tokyo University of Sciences. Professor Matsushima is a member of Cytimmune’s Scientific Advisory Board.